engleski

Is dipeptidyl peptidase IV activity associated with inflammation present in human rheumatoid arthritis and spondyloarthropaties?

Objective. The dipeptidyl peptidase IV (DPP IV) is a serine peptidase which has been suggested to play a role in the pathogenesis of rheumatoid arthritis (RA), but its mediator actions have not been well investigated in patients with spondyloarthropaties (SpA). The purpose of this study was to find an association between serum DPP IV activity and disease development in patients with RA and SpA, as well as investigate whether DPP IV could be a distinguishing marker in differentiation of these diseases. Methods. Clinical characteristics and demographic data which included age, sex and disease duration, as well as blood samples, were collected. According to the clinical presentation and laboratory data, 239 included patients were divided into two groups: 59 RA and 180 SpA patients. SpA group included psoriatic arthritis (n = 98), ankylosing spondylitis (n = 52) and reactive arthritis (n = 30) patients. The control group consisted of 65 healthy donors. Blood samples were used for assessment of laboratory parameters and determination of DPP IV activity which was determined in sera by a spectrophotometric method using the glicyl-prolyl-p-nitroanilid as substrate. Results. Serum DPP IV activity was significantly decreased in RA (median: 33.7 IU/L ; range 12.1 – 78.6) and SpA (median: 36.3 IU/L ; range: 8.0 – 90.1) patients compared to the control group (median: 45.8 IU/L ; range: 36.8 – 79.0). No difference was observed in serum DPP IV activity between RA and SpA groups of patients, as well as between patients with clinically active disease and remission. Conclusions. Our results suggest that serum DPP IV activity could not be used as a specific noninvasive clinical marker for different types of inflammatory arthritis, but could be potentially used as a nonspecific inflammatory marker.

Dipeptidyl peptidase IV (DPP IV); rheumatoid arthritis; spondyloarthropaties

nije evidentirano